Literature DB >> 16023183

Stromal osseous metaplasia in a low-grade ovarian adenocarcinoma.

P Mukonoweshuro1, A Oriowolo.   

Abstract

BACKGROUND: Stromal osseous metaplasia is a rare and curious finding in tumors of the ovary. CASE REPORT: The patient, a 66-year-old P3 G3 white female, had a past history of stage 1c left ovarian, well-differentiated endometrioid adenocarcinoma removed in 1981. She was treated with radiotherapy. The tumor recurred 21 years later with prominent stromal osseous metaplasia that had not been present in the primary. DISCUSSION: The pathogenesis of osseous metaplasia in epithelial tumors of the ovary is unclear; however, it is probable that a metaplastic process involving multipotential stromal stem cells results in bone formation.
CONCLUSION: Benign osseous metaplasia in ovarian tumors is rare and its histogenesis remains unclear. As far as we know, this process does not appear to have any prognostic or pathological significance.

Entities:  

Mesh:

Year:  2005        PMID: 16023183     DOI: 10.1016/j.ygyno.2005.05.040

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  4 in total

1.  Osseous metaplasia in ovarian tumours: a case with serous cystadenoma.

Authors:  D Miliaras; M Ketikidou; S Pervana
Journal:  J Clin Pathol       Date:  2007-05       Impact factor: 3.411

Review 2.  Plasticity of granulosa cells: on the crossroad of stemness and transdifferentiation potential.

Authors:  Edo Dzafic; Martin Stimpfel; Irma Virant-Klun
Journal:  J Assist Reprod Genet       Date:  2013-07-28       Impact factor: 3.412

3.  Bone Formation in a Mucinous Cystadenoma of the Ovary - Report of a Rare Case.

Authors:  Malek Kanani; Sara Yousefzadeh Shoushtari
Journal:  Maedica (Bucur)       Date:  2021-09

4.  Low-grade serous carcinoma with extensive osseous metaplasia arising from ovarian serous cystadenofibroma.

Authors:  Renan Ribeiro E Ribeiro; Ashley Valenzuela; Lindsey Beffa; C James Sung; M Ruhul Quddus
Journal:  Gynecol Oncol Rep       Date:  2021-01-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.